Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TELA Bio, Inc.TELA · Entity 7381 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TELA Bio, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,600 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 11,675 · Balance 23,600 F1: These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2036-06-09 | Direct | 17,335 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 17,335 · Balance 17,335 F2: The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
F2: The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 22:14 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 17,335 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0002089250-26-000001 · form4-06112026_100617.xml · derivative · entry 2 Rocchio Betty Jo · CIK 0002089250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,335 Underlying: Common Stock · 17,335 shares Expires 2036-06-09 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 22:14 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 11,675 | $0.00 | $0.00 |
DisclosureSEC source: 0002089250-26-000001 · form4-06112026_100617.xml · nonDerivative · entry 1 Rocchio Betty Jo · CIK 0002089250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,600 F1 · shares: These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 20:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 17,550 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0002089250-25-000004 · form4-10102025_081040.xml · derivative · entry 2 Rocchio Betty Jo · CIK 0002089250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,550 Underlying: Common Stock · 17,550 shares Expires 2035-10-09 F2 · derivative.exercise_date: The option vests in 36 equal monthly installments on each monthly anniversary of October 9, 2025, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 20:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 11,925 | $0.00 | $0.00 |
DisclosureSEC source: 0002089250-25-000004 · form4-10102025_081040.xml · nonDerivative · entry 1 Rocchio Betty Jo · CIK 0002089250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,925 F1 · shares: These restricted stock units will vest in three equal annual installments beginning on October 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.